ALFA Finder| Revenue growth | 14% YoY for FY26. |
|---|---|
| Margins | Stable outlook; currently around 32% vs historical 38%. |
| Demand visibility | Steady demand across markets; healthy volume traction. |
| Management confidence | High on long-term growth and execution discipline. |
Growth
Annual revenue grew 14% to ₹11,067 cr; Q4 PAT stood at ₹751 cr.
Outlook
Targeting double-digit revenue growth; ₹2,113 cr CWIP with ₹1,500 cr Kakinada expansion planned.
Risks
Geopolitical tensions in West Asia impacting freight costs and raw material lead times.
Earnings Call filed with BSE, NSE: DIVISLAB. Summary written with AI assistance from the document.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹11,442.00
- Market cap
- ₹3,03,749 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 90.3×Sector 43.7×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Investor Presentation: Key Takeaways
Q2 FY27 consolidated PAT ₹1,127 cr (+64% YoY) on total income ₹3,770 cr (+32%). H1 PAT ₹2,029 cr (+64%). CS is 62% of H1 sales; heavy capex cycle underway.
Divi's Laboratories Q2 FY27 Results: Net Profit ₹1,127 Cr, Up 63.6% YoY
Divi's Laboratories Ltd reported revenue from operations of ₹3,676 Cr (+35.4% YoY) and net profit of ₹1,127 Cr (+63.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,127 Cr · +63.6% YoY
Divi's Laboratories Board Meeting Date
Divi's Laboratories will hold a board meeting on November 07, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
Divi's Laboratories Other Announcement
Divis Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Regulation 31.
Divi's Laboratories Other Announcement
Immediate relatives of the company purchased 462 shares for a total consideration of Rs. 0.43 Crore in the open market.
- Value
- ₹0.43 Cr
Divi's Laboratories Other Announcement
Divis Laboratories Ltd reported a share pledge by Designated Person Nimmagadda Venkata Anirudh involving securities valued at ₹3.33 Crore. Additionally, Joshita Divi acquired shares worth ₹0.96 Crore via market purchase.
- Value
- ₹4.29 Cr